Literature DB >> 29986887

PBRM1 bromodomains variably influence nucleosome interactions and cellular function.

Mariesa J Slaughter1,2, Erin K Shanle3, Andrew W McFadden2, Emily S Hollis2, Lindsey E Suttle2, Brian D Strahl1,2,3, Ian J Davis4,2,5.   

Abstract

Chromatin remodelers use bromodomains (BDs) to recognize histones. Polybromo 1 (PBRM1 or BAF180) is hypothesized to function as the nucleosome-recognition subunit of the PBAF chromatin-remodeling complex and is frequently mutated in clear cell renal cell carcinoma (ccRCC). Previous studies have applied in vitro methods to explore the binding specificities of the six individual PBRM1 BDs. However, BD targeting to histones and the influence of neighboring BD on nucleosome recognition have not been well characterized. Here, using histone microarrays and intact nucleosomes to investigate the histone-binding characteristics of the six PBRM1 BDs individually and combined, we demonstrate that BD2 and BD4 of PBRM1 mediate binding to acetylated histone peptides and to modified recombinant and cellular nucleosomes. Moreover, we show that neighboring BDs variably modulate these chromatin interactions, with BD1 and BD5 enhancing nucleosome interactions of BD2 and BD4, respectively, whereas BD3 attenuated these interactions. We also found that binding pocket missense mutations in BD4 observed in ccRCC disrupt PBRM1-chromatin interactions and that these mutations in BD4, but not similar mutations in BD2, in the context of full-length PBRM1, accelerate ccRCC cell proliferation. Taken together, our biochemical and mutational analyses have identified BD4 as being critically important for maintaining proper PBRM1 function and demonstrate that BD4 mutations increase ccRCC cell growth. Because of the link between PBRM1 status and sensitivity to immune checkpoint inhibitor treatment, these data also suggest the relevance of BD4 as a potential clinical target.
© 2018 Slaughter et al.

Entities:  

Keywords:  BAF180; PBRM1; bromodomain; cancer; chromatin; chromatin regulation; chromatin structure; histone acetylation; histone methylation; histone modification; histones

Mesh:

Substances:

Year:  2018        PMID: 29986887      PMCID: PMC6120218          DOI: 10.1074/jbc.RA118.003381

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Structure and function of a human TAFII250 double bromodomain module.

Authors:  R H Jacobson; A G Ladurner; D S King; R Tjian
Journal:  Science       Date:  2000-05-26       Impact factor: 47.728

2.  The language of covalent histone modifications.

Authors:  B D Strahl; C D Allis
Journal:  Nature       Date:  2000-01-06       Impact factor: 49.962

Review 3.  Multivalent engagement of chromatin modifications by linked binding modules.

Authors:  Alexander J Ruthenburg; Haitao Li; Dinshaw J Patel; C David Allis
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

4.  Long-distance combinatorial linkage between methylation and acetylation on histone H3 N termini.

Authors:  Sean D Taverna; Beatrix M Ueberheide; Yifan Liu; Alan J Tackett; Robert L Diaz; Jeffrey Shabanowitz; Brian T Chait; Donald F Hunt; C David Allis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-06       Impact factor: 11.205

5.  A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Authors:  Deng Pan; Aya Kobayashi; Peng Jiang; Lucas Ferrari de Andrade; Rong En Tay; Adrienne M Luoma; Daphne Tsoucas; Xintao Qiu; Klothilda Lim; Prakash Rao; Henry W Long; Guo-Cheng Yuan; John Doench; Myles Brown; X Shirley Liu; Kai W Wucherpfennig
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

6.  The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p.

Authors:  D J Owen; P Ornaghi; J C Yang; N Lowe; P R Evans; P Ballario; D Neuhaus; P Filetici; A A Travers
Journal:  EMBO J       Date:  2000-11-15       Impact factor: 11.598

7.  Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions.

Authors:  Alexander J Ruthenburg; Haitao Li; Thomas A Milne; Scott Dewell; Robert K McGinty; Melanie Yuen; Beatrix Ueberheide; Yali Dou; Tom W Muir; Dinshaw J Patel; C David Allis
Journal:  Cell       Date:  2011-05-19       Impact factor: 41.582

8.  Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4.

Authors:  Yi-Jan Lin; Takashi Umehara; Makoto Inoue; Kohei Saito; Takanori Kigawa; Moon-Kyoo Jang; Keiko Ozato; Shigeyuki Yokoyama; Balasundaram Padmanabhan; Peter Güntert
Journal:  Protein Sci       Date:  2008-09-24       Impact factor: 6.725

9.  Peptide microarrays to interrogate the "histone code".

Authors:  Scott B Rothbart; Krzysztof Krajewski; Brian D Strahl; Stephen M Fuchs
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

10.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

View more
  9 in total

1.  BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.

Authors:  Dan-Dan He; Xue-Ying Shang; Na Wang; Guang-Xing Wang; Kun-Yan He; Lan Wang; Ze-Guang Han
Journal:  Oncogene       Date:  2022-01-11       Impact factor: 8.756

Review 2.  Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy.

Authors:  Marek Wanior; Andreas Krämer; Stefan Knapp; Andreas C Joerger
Journal:  Oncogene       Date:  2021-05-03       Impact factor: 8.756

3.  High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM1.

Authors:  Lili Liao; Nilda L Alicea-Velázquez; Lauren Langbein; Xiaohua Niu; Weijia Cai; Eun-Ah Cho; Meiling Zhang; Celeste B Greer; Qin Yan; Michael S Cosgrove; Haifeng Yang
Journal:  Mol Oncol       Date:  2019-02-02       Impact factor: 6.603

4.  PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.

Authors:  Xian-De Liu; Wen Kong; Christine B Peterson; Daniel J McGrail; Anh Hoang; Xuesong Zhang; Truong Lam; Patrick G Pilie; Haifeng Zhu; Kathryn E Beckermann; Scott M Haake; Sevinj Isgandrova; Margarita Martinez-Moczygemba; Nidhi Sahni; Nizar M Tannir; Shiaw-Yih Lin; W Kimryn Rathmell; Eric Jonasch
Journal:  Nat Commun       Date:  2020-05-01       Impact factor: 14.919

Review 5.  The Emerging World of Membrane Vesicles: Functional Relevance, Theranostic Avenues and Tools for Investigating Membrane Function.

Authors:  Aswin T Srivatsav; Shobhna Kapoor
Journal:  Front Mol Biosci       Date:  2021-04-22

6.  Bromodomains regulate dynamic targeting of the PBAF chromatin-remodeling complex to chromatin hubs.

Authors:  Charles A Kenworthy; Nayem Haque; Shu-Hao Liou; Panagiotis Chandris; Vincent Wong; Patrycja Dziuba; Luke D Lavis; Wei-Li Liu; Robert H Singer; Robert A Coleman
Journal:  Biophys J       Date:  2022-03-30       Impact factor: 3.699

7.  HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies.

Authors:  Mariesa J Slaughter; Erin K Shanle; Abid Khan; Katrin F Chua; Tao Hong; Lisa D Boxer; C David Allis; Steven Z Josefowicz; Benjamin A Garcia; Scott B Rothbart; Brian D Strahl; Ian J Davis
Journal:  Cell Rep       Date:  2021-01-19       Impact factor: 9.423

Review 8.  Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion.

Authors:  Peter Kreuzaler; Yulia Panina; Joanna Segal; Mariia Yuneva
Journal:  Mol Metab       Date:  2019-10-10       Impact factor: 7.422

9.  PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth.

Authors:  Weijia Cai; Liya Su; Lili Liao; Zongzhi Z Liu; Lauren Langbein; Essel Dulaimi; Joseph R Testa; Robert G Uzzo; Zhijiu Zhong; Wei Jiang; Qin Yan; Qing Zhang; Haifeng Yang
Journal:  Nat Commun       Date:  2019-12-20       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.